Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OVV-01 and IBR900 in Advanced Malignant Tumors
NCT05271279Phase 1Terminated
- Sponsor
- Beijing Boren Hospital
- Start
- Dec 2021
- Primary completion
- Aug 2022
- Modality
- Oncolytic Viruses, Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of OVV-01 and IBR900 in solid tumor (advanced stage) and lymphoma, sponsored by Beijing Boren Hospital. Primary endpoints: Dose Limiting Toxicity at 7 weeks and Adverse Events at 24 weeks. Started Dec 2021; status: terminated.
02
Drugs
OVV-01IBR900
03
Conditions
solid tumor (advanced stage)lymphoma
Beyond the preview
Go deeper on NCT05271279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05271279.